Raju Kandimalla Leaders
Early translational lead for AR-LDD. Translational Oncology scientist with over 10 years of expertise in developing multi-omics-based tissue as well as cfNA (Cell-free nucleic acid) biomarkers at the pan-cancer level to enable early detection, prognosis (molecular subtypes), and therapeutic prediction. Led several biomarker studies in solid tumors from hypotheses generation to assay development using the whole genome as well as target capture-based PCR/NGS methods in collaboration with academic and industry partners.
Proficiency in early translational development of oncology therapies in guiding target engagement biomarkers (PK/PD) and patient selection strategies. Expert in utilizing retrospective multi-omics datasets as well as generating prospective data from patient specimens to validate preclinical hypothesis/biomarkers and implement precision medicine. Planning and leading data analysis efforts together with bioinformaticians, clinical leads, and presenting the biomarker data/outcomes to cross-functional teams and key opinion leaders is my unique strength.
Adept in understanding the cross-talk of key cancer pathway interactions leading to primary/secondary resistance and validating the hypothesis in preclinical models and clinical specimens to guide rational combinations. Capable of implementing translational research plans including specimen collection, biomarker selection (targeted and exploratory), developing and validating assays internally/external vendors, and writing clinical protocols.
Excellent team player with demonstrated track record of success in cross-functional teams and involved in establishing external/academic collaborations to advance the scientific understanding and meet translational goals. Enjoys working with highly matrixed environment including biologists, medical directors, clinical teams, and bioinformaticians to support preclinical and clinical-stage oncology programs.
Published more than 35 high-impact manuscripts, expert reviews, secured patents, grants, and the DNA methylation-based urine biomarkers I discovered during my PhD are close to clinical translation by MDxHealth with a brand name “AssureMDx” for bladder cancer risk-prediction in hematuria patients.
